UT Southwestern has developed a simple blood test that can predict which patients with nonalcoholic fatty liver disease are most likely to develop liver cancer.
UT Southwestern has been ranked the No. 1 hospital in North Texas for the six years in a row, and ranked nationally for 9 specialties areas of health care.
A groundbreaking study showed a 100% response to immunotherapy for a type of rectal cancer. See what the findings mean, who might benefit, and what’s next.
A new radiation therapy approach offers curative potential for gynecologic tumors. Learn about adaptive radiation therapy (ART) and two clinical trials at UT Southwestern to help women with cancer.
The FDA has approved pembrolizumab immunotherapy, the first treatment to lower kidney cancer recurrence risk after surgery. UT Southwestern's Dr. Hans Hammers helps patients explore its benefits and risks.
David Sher, M.D. explains how a new clinical trial for head and neck cancer patients will study daily adaptive radiotherapy using tumor targeting driven by an AI-driven algorithm developed by UT Southwestern.
Daniel Bowers, M.D., Medical Director of the After the Cancer Experience program, discusses the importance of lifelong care for childhood cancer survivors.
As new CAR T-cell therapies are being approved to treat certain cancers, Ankit Kansagra, M.D., explains how the UT Southwestern team is working to further revolutionize treatment for more cancer patients.
Having a breast reconstruction fail is devastating. Dr. Teotia and Dr. Haddock at UTSW are pioneers in flap procedures. They work to improve recovery, and results.
PARP-1 inhibitor drugs can reduce the risk of BRCA- and HRDS-associated ovarian cancer by 70%. New research at UT Southwestern Medical Center may help expand treatment to more patients.
A new, FDA-approved four-drug combo for AL amyloidosis is improving longevity and quality of life dramatically. Ankit Kansagra, M.D., discusses how the medication and a multidisciplinary team of experts can give patients longer, healthier lives.
